The estimated Net Worth of Michael J. Detke is at least $4.27 Milhão dollars as of 10 August 2021. Michael Detke owns over 10,000 units of Cortexyme Inc stock worth over $19,500 and over the last 5 years he sold CRTX stock worth over $3,148,424. In addition, he makes $1,100,170 as Chief Medical Officer at Cortexyme Inc.
Michael has made over 5 trades of the Cortexyme Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of CRTX stock worth $22,300 on 10 August 2021.
The largest trade he's ever made was selling 58,261 units of Cortexyme Inc stock on 6 July 2021 worth over $3,148,424. On average, Michael trades about 12,065 units every 69 days since 2020. As of 10 August 2021 he still owns at least 10,000 units of Cortexyme Inc stock.
You can see the complete history of Michael Detke stock trades at the bottom of the page.
Dr. Michael Detke M.D., Ph.D. serves as Chief Medical Officer of the Company. Dr. Detke has over 25 years of research experience and extensive clinical and drug development expertise. Prior to joining Cortexyme, Dr. Detke served as the Chief Medical Officer at Embera NeuroTherapeutics, Inc. from September 2016 to December 2018, and he served as President of Detke Biopharma Consulting LLC from April 2013 to December 2018, including as Chief Medical Officer for CoMentis Pharmaceuticals. He served as Chief Medical Officer and Director of the MedAvante Research Institute of MedAvante, Inc. Dr. Detke joined MedAvante from Eli Lilly, Inc. where he served as Executive Director and head of early phase development of CNS therapeutics. At Lilly, he led clinical development of one of the industry’s deepest and strongest pipelines of CNS products. He served as Senior Medical Director responsible for Phase III development for Cymbalta and Phase IV for Prozac. Dr. Detke has served as an Adjunct volunteer Clinical Professor of Psychiatry at Indiana University School of Medicine since July 2000. Dr. Detke holds a B.A. and M.S. in Psychology from Yale University and an M.A., M.D. and Ph.D. in Psychology and Behavioral Pharmacology from the University of Pennsylvania. He also received post-doctoral training in Psychiatry from Harvard Medical School.
As the Chief Medical Officer of Cortexyme Inc, the total compensation of Michael Detke at Cortexyme Inc is $1,100,170. There are no executives at Cortexyme Inc getting paid more.
Michael Detke is 53, he's been the Chief Medical Officer of Cortexyme Inc since 2018. There are 9 older and 8 younger executives at Cortexyme Inc. The oldest executive at Cortexyme Inc is Una Ryan, 78, who is the Lead Independent Director.
Michael's mailing address filed with the SEC is C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi, eAnsbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: